131 related articles for article (PubMed ID: 17725485)
21. Abrogation of prostaglandin E-EP4 signaling in osteoblasts prevents the bone destruction induced by human prostate cancer metastases.
Watanabe K; Tominari T; Hirata M; Matsumoto C; Maruyama T; Murphy G; Nagase H; Miyaura C; Inada M
Biochem Biophys Res Commun; 2016 Sep; 478(1):154-161. PubMed ID: 27450806
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of vitamin D analogs as therapeutic agents for prostate cancer.
Chen TC; Holick MF; Lokeshwar BL; Burnstein KL; Schwartz GG
Recent Results Cancer Res; 2003; 164():273-88. PubMed ID: 12899529
[TBL] [Abstract][Full Text] [Related]
23. Vitamin D deficiency promotes prostate cancer growth in bone.
Zheng Y; Zhou H; Ooi LL; Snir AD; Dunstan CR; Seibel MJ
Prostate; 2011 Jun; 71(9):1012-21. PubMed ID: 21541977
[TBL] [Abstract][Full Text] [Related]
24. VDR in Osteoblast-Lineage Cells Primarily Mediates Vitamin D Treatment-Induced Increase in Bone Mass by Suppressing Bone Resorption.
Nakamichi Y; Udagawa N; Horibe K; Mizoguchi T; Yamamoto Y; Nakamura T; Hosoya A; Kato S; Suda T; Takahashi N
J Bone Miner Res; 2017 Jun; 32(6):1297-1308. PubMed ID: 28177161
[TBL] [Abstract][Full Text] [Related]
25. Osteoblasts suppress high bone turnover caused by osteolytic breast cancer in-vitro.
Krawetz R; Wu YE; Rancourt DE; Matyas J
Exp Cell Res; 2009 Aug; 315(14):2333-42. PubMed ID: 19433087
[TBL] [Abstract][Full Text] [Related]
26. Host-derived RANKL is responsible for osteolysis in a C4-2 human prostate cancer xenograft model of experimental bone metastases.
Morrissey C; Kostenuik PL; Brown LG; Vessella RL; Corey E
BMC Cancer; 2007 Aug; 7():148. PubMed ID: 17683568
[TBL] [Abstract][Full Text] [Related]
27. Osteolytic prostate cancer cells induce the expression of specific cytokines in bone-forming osteoblasts through a Stat3/5-dependent mechanism.
Schulze J; Albers J; Baranowsky A; Keller J; Spiro A; Streichert T; Zustin J; Amling M; Schinke T
Bone; 2010 Feb; 46(2):524-33. PubMed ID: 19796718
[TBL] [Abstract][Full Text] [Related]
28. Effect of Id1 knockdown on formation of osteolytic bone lesions by prostate cancer PC3 cells in vivo.
Zhang Z; Li K; Zhang X; Fang Z; Xiong W; Chen Q; Chen W; Li F
J Huazhong Univ Sci Technolog Med Sci; 2012 Jun; 32(3):364-369. PubMed ID: 22684559
[TBL] [Abstract][Full Text] [Related]
29. [
Janssen JC; Woythal N; Meißner S; Prasad V; Brenner W; Diederichs G; Hamm B; Makowski MR
Mol Imaging Biol; 2017 Dec; 19(6):933-943. PubMed ID: 28707038
[TBL] [Abstract][Full Text] [Related]
30. Differences of osteoblastic bone metastases and osteolytic bone metastases in clinical features and molecular characteristics.
Fang J; Xu Q
Clin Transl Oncol; 2015 Mar; 17(3):173-9. PubMed ID: 25351174
[TBL] [Abstract][Full Text] [Related]
31. Osteoprotegerin in prostate cancer bone metastasis.
Corey E; Brown LG; Kiefer JA; Quinn JE; Pitts TE; Blair JM; Vessella RL
Cancer Res; 2005 Mar; 65(5):1710-8. PubMed ID: 15753366
[TBL] [Abstract][Full Text] [Related]
32. Bone-targeting agents in prostate cancer.
Suzman DL; Boikos SA; Carducci MA
Cancer Metastasis Rev; 2014 Sep; 33(2-3):619-28. PubMed ID: 24398856
[TBL] [Abstract][Full Text] [Related]
33. Pathogenesis of osteoblastic bone metastases from prostate cancer.
Ibrahim T; Flamini E; Mercatali L; Sacanna E; Serra P; Amadori D
Cancer; 2010 Mar; 116(6):1406-18. PubMed ID: 20108337
[TBL] [Abstract][Full Text] [Related]
34. Targeting factors involved in bone remodeling as treatment strategies in prostate cancer bone metastasis.
Vessella RL; Corey E
Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6285s-6290s. PubMed ID: 17062715
[TBL] [Abstract][Full Text] [Related]
35. TMPRSS2:ERG gene fusion expression regulates bone markers and enhances the osteoblastic phenotype of prostate cancer bone metastases.
Delliaux C; Tian TV; Bouchet M; Fradet A; Vanpouille N; Flourens A; Deplus R; Villers A; Leroy X; Clézardin P; de Launoit Y; Bonnelye E; Duterque-Coquillaud M
Cancer Lett; 2018 Dec; 438():32-43. PubMed ID: 30201302
[TBL] [Abstract][Full Text] [Related]
36. Vitamin D deficiency promotes human breast cancer growth in a murine model of bone metastasis.
Ooi LL; Zhou H; Kalak R; Zheng Y; Conigrave AD; Seibel MJ; Dunstan CR
Cancer Res; 2010 Mar; 70(5):1835-44. PubMed ID: 20160035
[TBL] [Abstract][Full Text] [Related]
37. Establishment and validation of an in vitro co-culture model to study the interactions between bone and prostate cancer cells.
Nordstrand A; Nilsson J; Tieva A; Wikström P; Lerner UH; Widmark A
Clin Exp Metastasis; 2009; 26(8):945-53. PubMed ID: 19728119
[TBL] [Abstract][Full Text] [Related]
38. Differential effects of 1,25-dihydroxyvitamin D3-analogs on osteoblast-like cells and on in vitro bone resorption.
van den Bemd GJ; Pols HA; Birkenhäger JC; Kleinekoort WM; van Leeuwen JP
J Steroid Biochem Mol Biol; 1995 Dec; 55(3-4):337-46. PubMed ID: 8541230
[TBL] [Abstract][Full Text] [Related]
39. Preclinical evaluation of zoledronate using an in vitro mimetic cellular model for breast cancer metastatic bone disease.
Dedes PG; Kanakis I; Gialeli Ch; Theocharis AD; Tsegenidis T; Kletsas D; Tzanakakis GN; Karamanos NK
Biochim Biophys Acta; 2013 Jun; 1830(6):3625-34. PubMed ID: 23395844
[TBL] [Abstract][Full Text] [Related]
40. New 19-nor-(20S)-1alpha,25-dihydroxyvitamin D3 analogs strongly stimulate osteoclast formation both in vivo and in vitro.
Sato M; Nakamichi Y; Nakamura M; Sato N; Ninomiya T; Muto A; Nakamura H; Ozawa H; Iwasaki Y; Kobayashi E; Shimizu M; DeLuca HF; Takahashi N; Udagawa N
Bone; 2007 Feb; 40(2):293-304. PubMed ID: 17070129
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
